T cell therapies.
T cell therapies are increasingly used for the treatment of malignancies and viral-associated diseases. Initial studies focused on the use of unmanipulated T cell populations after allogeneic stem cell transplantation. More recently, the use of antigen-specific T cells has been explored. This chapter reviews the clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) for the treatment of EBV-associated malignancies. Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens.
Gottschalk
S
S
Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3-3320, 77030 Houston, USA. smg@bcm.edu
Bollard
C M
CM
Straathof
K C
KC
Louis
C U
CU
Savoldo
B
B
Dotti
G
G
Brenner
M K
MK
Heslop
H E
HE
Rooney
C M
CM
D000818:Animals; D004854:Herpesvirus 4, Human; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D008232:Lymphoproliferative Disorders / Q000628:therapy; D009303:Nasopharyngeal Neoplasms / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D017735:Virus Latency